London
· Delayed Price · Currency is GBP · Price in USD Moleculin Biotech Statistics
Total Valuation
Moleculin Biotech has a market cap or net worth of GBP 3.65 million. The enterprise value is -3.51 million.
| Market Cap | 3.65M |
| Enterprise Value | -3.51M |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +37.97% |
| Shares Change (QoQ) | +46.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.16 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.19 |
Financial Position
The company has a current ratio of 2.08, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.08 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -141.49% and return on invested capital (ROIC) is -82.70%.
| Return on Equity (ROE) | -141.49% |
| Return on Assets (ROA) | -57.45% |
| Return on Invested Capital (ROIC) | -82.70% |
| Return on Capital Employed (ROCE) | -162.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.25M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.82% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -79.82% |
| 50-Day Moving Average | 2.76 |
| 200-Day Moving Average | 11.66 |
| Relative Strength Index (RSI) | 32.70 |
| Average Volume (20 Days) | 255 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.57M |
| Pretax Income | -22.49M |
| Net Income | -22.49M |
| EBITDA | -21.48M |
| EBIT | -21.57M |
| Earnings Per Share (EPS) | -8.37 |
Balance Sheet
The company has 7.02 million in cash and 377,527 in debt, giving a net cash position of 6.64 million.
| Cash & Cash Equivalents | 7.02M |
| Total Debt | 377,527 |
| Net Cash | 6.64M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.58M |
| Book Value Per Share | 1.86 |
| Working Capital | 4.49M |
Cash Flow
In the last 12 months, operating cash flow was -18.05 million and capital expenditures -70,133, giving a free cash flow of -18.12 million.
| Operating Cash Flow | -18.05M |
| Capital Expenditures | -70,133 |
| Free Cash Flow | -18.12M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Moleculin Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.97% |
| Shareholder Yield | -37.97% |
| Earnings Yield | -616.85% |
| FCF Yield | -496.75% |
Stock Splits
The last stock split was on March 22, 2024. It was a reverse split with a ratio of 0.0666666667.
| Last Split Date | Mar 22, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0666666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |